Christopher Viehbacher, CEO of Sanofi-aventis, is now chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors. Viehbacher took the role following the resignation of Jeffrey Kindler, who has also stepped down as CEO of Pfizer.
McKesson has named Brian Tyler as president of its US pharmaceutical distribution unit. Tyler has held a number of positions during 13 years at McKesson, most recently as senior vice president of strategy and business development for all of McKesson distribution solutions.
Robert Ingram, the former CEO of Glaxo Wellcome, has been appointed to the board of directors at Elan. Ingram will succeed Kyran McLaughlin as chairman in January 2011.
GeoVax Labs has elected David Dodd as chairman of the board, replacing Donald Hildebrand. Dodd has executive healthcare experience from time at RiversEdge BioVentures, BioReliance, Serologicals and Solvay Pharmaceuticals.
Frank Baldino Jr, chairman and CEO of Cephalon, is to remain on a medical leave of absence indefinitely and will not resume his duties in 2010. In the absence of the CEO Kevin Buchi, chief operating officer at Cephalon, will perform Baldino’s day-to-day responsibilities.
Selventa has promoted David de Graaf to president and CEO from chief scientific officer. Before joining Selventa de Graaf worked at Boehringer-Ingelheim, Pfizer and AstraZeneca.
Alberto Martinez has joined the board of directors at Celsion. Martinez has previously worked at Talecris Biotherapeutics, CSL Behring, Aventis Behring and Sandoz Pharmaceutical.
Otonomy has named David Weber as president, CEO and member of the board of directors, replacing Jay Lichter who will continue as a member of the board of directors. Weber has worked at MacuSight and Oculex Pharmaceuticals.